<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820363</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN001 - FORTIFY</org_study_id>
    <nct_id>NCT02820363</nct_id>
  </id_info>
  <brief_title>Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures</brief_title>
  <official_title>A Prospective, Randomized Multicenter Controlled Trial of CERAMENT™|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BONESUPPORT AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BONESUPPORT AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of CERAMENT™|G used
      in conjunction with standard-of-care treatment compared to standard-of-care treatment alone
      in the care of subjects with open fractures of the tibial diaphysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CERAMENT™|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony
      voids or gaps which are not intrinsic to the stability of the bony structure and where there
      is risk of bacterial contamination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of absence of deep infection at fracture site, absence of secondary procedures intended to promote fracture union, and improvement in the SF-36v2 PCS.</measure>
    <time_frame>12 months</time_frame>
    <description>Absence of secondary procedures, absence of infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious device related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>for the test (CERAMENT™|G) arm</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Tibial Fracture</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tibial fracture fixation with IM nail.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CERAMENT|G</intervention_name>
    <description>Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids.</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SOC treatment</intervention_name>
    <description>surgical repair of tibial fracture</description>
    <arm_group_label>Test</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Male or female 18-21 years of age with radiographic evidence on plain x-rays of
             proximal and distal tibial physeal closure, OR male or female 22-75 years of age

          2. Gustilo-Anderson Grade II, IIIA, or IIIB open tibial shaft fracture (with or without
             extension into the meta-epiphyseal region) amenable to fixation with an
             intramedullary nail

          3. Bone loss at the fracture site must have a radiographic apparent bone gap (RABG)
             between 5 and 27.5 millimeters.

          4. Life expectancy of at least 1 year

          5. Patient is willing to provide informed consent, is geographically stable and able to
             comply with the required follow up visits, testing schedule and medication regimen

          6. Adequate soft tissue coverage at the fracture site (through primary closure or
             surgical reconstruction, including local and free soft tissue transfer)

          7. Definitive wound closure within 10 days of the initial injury

          8. Unilateral fracture, or, in the case of individually-qualifying bilateral open tibia
             fractures, the more severe of the bilateral fractures.

        Patients will be excluded if ANY of the following conditions apply:

          1. Pregnant or breastfeeding women or planning on becoming pregnant during the
             investigational period

          2. Patient is currently participating in an investigational drug or other device study
             or previously enrolled in this study

          3. Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/L or
             being treated with dialysis

          4. Known hypersensitivity to aminoglycoside antibiotics, calcium sulfate or calcium
             hydroxyapatite

          5. Pre-existing calcium metabolism disorder

          6. Uncontrolled diabetes mellitus (hemoglobin A1c levels &gt; 10%)

          7. A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's
             disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder,
             Ehler-Danlos syndrome, osteogenesis imperfecta)

          8. Neuromuscular disorders such as myasthenia gravis or Parkinson's disease

          9. Currently has untreated malignant neoplasm(s), or is currently undergoing radiation
             therapy or chemotherapy

         10. Inadequate neurovascular status in the involved limb that may jeopardize healing
             (e.g., Gustilo-Anderson IIIc classification)

         11. Patients who have a preexisting shaft deformity that cannot accommodate a nail or a
             previous history of osteomyelitis in the index limb

         12. Ipsilateral tibial plateau or pilon/plafond fractures

         13. Other ipsilateral lower extremity fracture(s) if, in the opinion of the investigator,
             the treatment and/or rehabilitation of such fracture(s) will substantially interfere
             with the treatment, rehabilitation or other requirements outlined in this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas R. Dirschl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Chicago Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Mundstock, BS</last_name>
    <phone>612-554-1399</phone>
    <email>erin.mundstock@bonesupport.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon McFadden, DVM</last_name>
    <phone>612-749-9387</phone>
    <email>sharon.mcfadden@bonesupport.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Geoffrey Marecek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Orthopedic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Louis Kwong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Hak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul Matuszewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emily Wagstrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Brett Crist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lisa Cannada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rick Gehlert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University, Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philipp Leucht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Archdeacon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedics Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kyle Jeray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Obremskey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Animesh Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>June 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wound</keyword>
  <keyword>open fracture</keyword>
  <keyword>fracture</keyword>
  <keyword>tibial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
